ABBV-951 FDA Approval Status

FDA Approved: No
Brand name: ABBV-951
Generic name: foscarbidopa and foslevodopa
Company: AbbVie Inc.
Treatment for: Parkinson's Disease

ABBV-951 (foscarbidopa/foslevodopa) is a solution of carbidopa and levodopa prodrugs for continuous subcutaneous delivery that is being investigated for the treatment of motor fluctuations in patients with advanced Parkinson's disease.

ABBV-951 is designed to provide a first-of-its-kind, 24-hour, continuous subcutaneous delivery of carbidopa/levodopa (CD/LD). Compared to oral CD/LD, it offers the potential for improvement in motor fluctuations in patients with advanced Parkinson's disease.

Development timeline for ABBV-951

Date	Article
Jun 25, 2024	AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)
Mar 22, 2023	AbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application
May 20, 2022	AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for the Treatment of Advanced Parkinson's Disease
Oct 28, 2021	AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with Advanced Parkinson's Disease

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer